Silence Therapeutics plc Announces Completion Of Merger With Intradigm Corporation And Issue Of New Shares
1/6/2010 2:12:08 PM
More...
|
Silence Therapeutics plc Agrees to Buy Intradigm Corporation in a Share-Swap Deal Worth $26 Million
12/16/2009 6:29:03 AM
More...
|
Intradigm Corporation Announces Issuance of RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
5/19/2009 11:25:55 AM
More...
|
Intradigm Corporation Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
3/17/2009 10:51:47 AM
More...
|
Intradigm Corporation Closes Final Tranche of $21.4 Million Series B Financing; Philip Haworth, Ph.D. Appointed Chief Executive Officer
1/7/2009 6:50:27 AM
More...
|
Intradigm Corporation Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics Zamore Patent Covers Methods for Enhancing RNAi Structural Features and Strengthens Intradigm's Competitive Position
12/2/2008 9:34:03 AM
More...
|
Intradigm Corporation Raises $18.5 Million in Series B Financing
10/2/2008 6:34:40 AM
More...
|
Intradigm Corporation Announces Allowance of Key RNA Interference (RNAi) Patent
6/17/2008 11:13:28 AM
More...
|
Study Shows Intradigm Corporation's RNAi Nanoplex Technology To Be Effective
4/14/2008 10:27:57 AM
More...
|
Intradigm Corporation Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
4/9/2008 8:36:49 AM
More...
|
|